Dinner Symposium: Harnessing Immune Responses and Stem Cell Transplantation as a Paradigm of Combination Therapy in Cancer
November 2, 2007
Seaport Hotel
Boston, Massachusetts
Dinner Symposium Offers 1.75 CME Credits
The Dinner Symposium has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of the Clinical Immunology Society and the International Society for Biological Therapy of Cancer. The Clinical Immunology Society is accredited by the ACCME to provide continuing medical education for physicians.
The Clinical Immunology Society designates this educational activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim credit commensurate with the extent of their participation in the activity.
Intended Audiences
The target audience for this program includes basic scientists and clinical investigators from academia, industry, and regulatory agencies. The audience will include clinicians, researchers, students, post-doctoral fellows, and allied health professionals.
Program Objectives
- Instill a dialogue of the most recent advances utilizing immunotherapies (cellular as well as molecular targeting) in combination with hematopoietic stem cell transplantation (HSCT) in the treatment of cancer
- Facilitate communication and collaborations between laboratory and clinical investigators
- Provide a forum for enhanced interactions among the pharmaceutical industry, government, and academia in order to facilitate cancer research with combination therapies that may lead to better patient outcomes
- Discuss potential synergies in efficacy as well as potential toxicities using immunotherapy or molecular targeting in the context of HSCT in cancer and to explore potentially novel interactions of immunotherapy taking place in the context of HSCT
- Educate students, post-doctoral fellows, and junior faculty in the area of HSCT and offer an opportunity to interact with senior investigators and leaders in the field.
Expected Outcomes:
- Attendees will learn about the most recent advances involving HSCT in cancer
- Clinical and laboratory investigators will initiate productive collaborations
- Pharmaceutical academic investigators will collaborate on the formulation of novel clinical trials or experimental ideas, which may lead to better outcomes in cancer patients
Claiming CME
Email correspondence will be sent to all attendees at the conclusion of this program with specific instructions to claim a CME certificate.
Click here to claim your CME credits.
|